Home > News > Recent cases

Idenix v Gilead [2014] EWHC 3916 (Pat)19 July 2016Andrew Lykiardopoulos QC, Tom Moody-Stuart and William Duncan all acted for Gilead (together with Justin Turner QC) in these patent infringement proceedings brought by Idenix in respect of Gilead’s product “Sovaldi” . The trial was heard over three weeks before Arnold J in 2014, who dismissed Idenix’s claims of patent infringement and held in favour […]
Glaxo Wellcome UK Ltd (t/a Allen & Hansburys) v Sandoz Ltd (High Court) [2016] EWHC 1537 (Ch)28 June 2016This case concerns an ongoing and large scale action for Trade Mark infringement and passing off brought by Glaxo against Sandoz in relation to asthma inhalers. The UK action forms part of a series of international disputes concerning these pharmaceutical products. Glaxo owns a EUTM colour per se trade mark which is visually represented by […]
Hospira UK Ltd -v-Cubist Pharmaceuticals LLC [2016] EWHC 1285 (PAT)10 June 2016Richard Meade QC and Isabel Jamal represented Hospira against Cubist Pharmaceuticals in this three-patent validity trial. Hospira successfully invalidated all three patents on the basis of obviousness over various pieces of prior art. The patents concerned dosing regimens and methods of purification of a drug called daptomycin, which is used to treat gram positive infections […]
R (British American Tobacco UK Limited & Ors) v Secretary of State for Health19 May 2016In R (British American Tobacco UK Limited & Ors) v Secretary of State for Health, the High Court was asked to consider the lawfulness of the Standardised Packaging of Tobacco Products Regulations 2015. Similar measures were adopted in Australia in 2011. The tobacco company claimants relied upon 15 grounds of challenge. The grounds included proportionality, […]
GlaxoSmithKline UK Limited-and-Wyeth Holdings LLC [2016] EWHC 1045 (CH)12 May 2016Michael Tappin QC and William Duncan appeared for the successful patentee in this claim for revocation by GSK and counterclaim for infringement by Wyeth. The patent related to meningitis B vaccines, identifying a valuable new vaccine candidate now known as factor H binding protein, that forms part of GSK’s Bexsero vaccine. The attacks against the […]